Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies
Haemophilia · 2024
DOI: 10.1111/hae.14976 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Haemophilia, 2024. Verfasst von Maria Elisa Mancuso und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Hemostatics. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Introduction
Over the last decades progress in haemophilia treatment has been remarkable and prophylaxis with clotting factor concentrates in haemophilia A and B has been established as the standard of care in individuals with haemophilia and a severe bleeding phenotype. Besides clotting factor products with prolonged half‐life non‐factor therapies were developed which enable prophylaxis via subcutaneous administration. Factor VIIIa mimetics like emicizumab facilitate the coagulation pathway and are used in routine clinical practice for indivdiduals with haemophilia A. Rebalancing therapeutic agents like fitusiran, concizumab, marstacimab and serpin PC block the anticoagulant pathway and clinical trials using these products in individuals with haemophilia A and B are ongoing. Aim and Methods A narrative review to asess the benefits and risks of non‐factor therapies taking in to account re‐defined haemophilia treatment goals.
Results
Prophylaxis for prevention of bleeds using non‐factor products by subcutaneous administration is effective and results in reductions of bleeding episodes in individuals with haemophilia A or B with and without inhibitors. The treatment with emicizumab showed tolerable safety both in clinical trials and long‐term real‐world observations with few thrombotic events. In some clinical trials with rebalancing therapies (fitusiran and concizumab) thrombotic events occurred. Monitoring of the haemostatic function of novel therapies especially with concomitant haemostatic treatment is not yet established.
Conclusion
With the advent of novel therapeutic agents including factor concentrates with ultra‐long half‐life and improved FVIIIa mimetics aimed at raising the bar of protection into the non‐hemophilic range redefinition of haemophilia treatment goals is eagerly needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Humanitas University, Pieve Emanuele, Milan, Italy.
- Boston Children's Hospital, Boston Hemophilia Center, Harvard Medical School, Boston, USA.
- Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
- Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
ORCID-Profile: Maria Elisa Mancuso, Stacy E Croteau, Robert Klamroth
Zitieren
APA
Mancuso, M. E., Croteau, S. E., & Klamroth, R. (2024). Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia. https://doi.org/10.1111/hae.14976
Vancouver
Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024. doi:10.1111/hae.14976
BibTeX
@article{Mancuso2024,
author = {Mancuso, Maria Elisa and Croteau, Stacy E and Klamroth, Robert},
title = {Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14976}
}
EUVIMED